Below is a list of individual analysts that we are aware of that currently follow ContraVir Pharmaceuticals. 

Please note, that any opinions, estimates or forecasts regarding performance made by these analysts do not represent ContraVir Pharmaceuticals or its management team.  ContraVir Pharmaceuticalsis under no obligation to update this list, thus it may not be complete or up to date.


David Bautz, Ph.D.

Zacks Investment Research, Inc.
(312) 265-9471
dbautz@zacks.com
   

Kumaraguru Raja, Ph.D.

Noble Life Science Partners
(212) 863-3225
kraja@noblelsp.com
     

Jason Kolbert

Maxim Group, LLC
(212) 895-3516
jkolbert@maximgrp.com
    

James Molloy

Laidlaw & Company
(857) 317-5061
jmolloy@laidlawltd.com
    

 

 


print email